ReviewJournal of pharmaceutical analysis2026
Advances in aptamer technology for target-based drug discovery.
Review in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Innovations in Aptamer Technology: SELEX To Intelligent Molecular Engineering and Clinical Translation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Advances in the Control of Plant Fungal Pathogens.Journal of fungi (Basel, Switzerland) · 2026Review
- Multidisciplinary cutting-edge technologies accelerating target-based drug discovery.Journal of pharmaceutical analysis · 2026Article
- Aptamer-based technologies for extracellular vesicle analysis and engineering: from isolation to functional applications.Extracellular vesicles and circulating nucleic acids · 2026Review
- Aptamers and aptamer-drug conjugates as synthetic immune modulators for cancer immunotherapy.Frontiers in immunology · 2026Review
- Harnessing in Silico Design for Electrochemical Aptasensor Optimization: Detection of Okadaic Acid (OA).Biosensors · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aptamer therapeutics represent a class of target-based therapies that leverage their high specificity and affinity for diverse molecular targets. As single-stranded DNA or RNA oligonucleotides, aptamers offer advantages in therapeutic applications. A critical aspect of aptamer drug development is the selection process, which has seen significant advancements through various
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.